Condensed Consolidated Statements of Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Revenues:
Collaborative research and development	$ 524	$ 372	$ 1,125	$ 6,108
Royalty income	404	218	1,121	730
Total revenues	928	590	2,246	6,838
Operating expenses:
Research and development	3,325	3,324	11,413	10,667
General and administrative	2,281	2,426	7,325	8,611
Total operating expenses	5,606	5,750	18,738	19,278
Loss from operations	(4,678)	(5,160)	(16,492)	(12,440)
Interest and other income	25	20	74	71
Change in fair value of derivative liability	(2,325)	0	(2,325)	0
Net loss	$ (6,978)	$ (5,140)	$ (18,743)	$ (12,369)
Net loss per common share:
Basic and diluted	$ (0.15)	$ (0.15)	$ (0.43)	$ (0.36)
Weighted average common shares:
Basic and diluted	45,644	34,366	43,184	34,238
Net loss	$ (6,978)	$ (5,140)	$ (18,743)	$ (12,369)
Other comprehensive income (loss):
Foreign currency translation adjustments	1	0	4	(30)
Net unrealized gain on marketable securities	0	1	0	2
Other comprehensive income (loss)	1	1	4	(28)
Comprehensive loss	$ (6,977)	$ (5,139)	$ (18,739)	$ (12,397)